half-hour program, which is part of the "Shape of Things
to Come" series explores new directions in research
that seek it aid in the prevention and treatment of potentially
life-threatening diseases (including cancer, heart disease,
neurological disorders, etc.). In addition, the next generation
of biomaterials and biomedical products that aid in the
delivery of drugs will be examined. These new technologies
offer hope to millions of individuals living with chronic
conditions. Additionally, the panel will address the length
of time spent in research, its cost and the painstaking
process of finding new ways to prevent and manage disease.
The panel is comprised of two academic scientific researchers,
a representative from the pharmaceutical and medical technology
industry, and an economist from a pharmaceutical company.
Dr. William Welsh |
Dr. Neal Masia |
Dr. William Welsh – Director of the
Informatics Institute at the University of Medicine and
Dentistry of New Jersey.
Dr. Neal Masia – Director of Economic
Policy at Pfizer Incorporated.
William Healy – Executive Vice President
of the HealthCare Institute of New Jersey.